This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent. Top assignee: Replicor Inc. Active years: 2008-2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008-2011
Title: Jean-Marc Juteau: Innovating Antiviral Therapies
Introduction
Jean-Marc Juteau, a prominent inventor based in Blainville, Canada, has made significant contributions to the field of antiviral research. With a total of four patents under his name, he is at the forefront of developing novel therapeutic agents against viral infections and cancer caused by oncoviruses.
Latest Patents
Among Jean-Marc Juteau's latest innovations are two notable patents focused on antiviral oligonucleotides targeting hepatitis B virus (HBV). These patents describe random sequence oligonucleotides that exhibit antiviral activity and are typically greater than 40 nucleotides in length. The inventions not only detail their effectiveness as antiviral agents but also outline methods for the prophylaxis and treatment of viral infections in humans and animals. Importantly, the methods include administering a pharmacologically acceptable, therapeutically effective amount of oligonucleotides that do not function by a sequence complementary mode of action, thus broadening the horizons of antiviral therapies.
Career Highlights
Jean-Marc Juteau's career has been marked by his innovative approach to biotechnology, particularly through his work at Replicor Inc. His focus on developing cutting-edge antiviral treatments positions him as a key player in the industry. Juteau’s inventive spirit is evident in his successful patent applications, which reflect both his dedication to research and his commitment to addressing critical health challenges.
Collaborations
In his pursuit of innovation, Jean-Marc collaborates closely with Andrew Vaillant, a fellow researcher at Replicor Inc. Together, they strive to enhance the understanding and application of antiviral therapies, contributing to the advancement of medical science and offering hope for effective treatment options against viral diseases.
Conclusion
Jean-Marc Juteau stands out as a pioneering inventor in the realm of antiviral research. With multiple patents to his name and a focus on innovative treatments, he continues to push the boundaries of science to improve health outcomes for individuals affected by viral infections and cancers related to oncoviruses. His work at Replicor Inc. and collaborations with colleagues like Andrew Vaillant embody the spirit of innovation and dedication required to advance medical therapies in today's challenging landscape.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile